triazolam has been researched along with caffeine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mattila, ME; Mattila, MJ; Nuotto, E | 1 |
| Bickel, WK; Fenwick, JW; Higgins, ST; Hughes, JR; Oliveto, AH; Shea, PJ | 1 |
| Freeman, CR; Gomez, SA; Johnson, LC; Spinweber, CL | 1 |
| Roehrs, T; Roth, T; Smith, D; Zorick, F; Zwyghuizen-Doorenbos, A | 1 |
| Goldman, NH; Madakasira, S; Rowlett, JK; Rush, CR; Woolverton, WL | 1 |
| Badger, GJ; Bickel, WK; Hughes, JR; Kamien, JB; Smith, BJ | 1 |
| Badger, G; Bickel, WK; Higgins, ST; Hughes, JR; Oliveto, AH | 1 |
| Bickel, WK; Smith, BJ | 2 |
| Baker, RW; Rowlett, JK; Rush, CR | 1 |
1 review(s) available for triazolam and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 trial(s) available for triazolam and caffeine
| Article | Year |
|---|---|
Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects.
Topics: Anti-Anxiety Agents; Azabicyclo Compounds; Caffeine; Double-Blind Method; Humans; Piperazines; Psychomotor Performance; Reference Values; Triazolam | 1992 |
Reversal by caffeine of triazolam-induced impairment of waking function.
Topics: Adult; Arousal; Caffeine; Humans; Hypnotics and Sedatives; Male; Memory; Psychomotor Performance; Sleep; Triazolam; Wakefulness | 1988 |
Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.
Topics: Adult; Caffeine; Discrimination Learning; Dose-Response Relationship, Drug; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Pentobarbital; Pyridines; Triazolam; Zolpidem | 1997 |
Secobarbital in humans discriminating triazolam under two-response and novel-response procedures.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Secobarbital; Triazolam | 1997 |
Functional antagonism of the caffeine-discriminative stimulus by triazolam in humans.
Topics: Adult; Anti-Anxiety Agents; Buspirone; Caffeine; Central Nervous System Stimulants; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Interactions; Generalization, Stimulus; Humans; Hypnotics and Sedatives; Male; Psychomotor Performance; Triazolam | 1997 |
Flumazenil discrimination by humans under a two-response and a novel-response procedure.
Topics: Adolescent; Adult; Caffeine; Central Nervous System Stimulants; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Flumazenil; GABA Modulators; Humans; Male; Midazolam; Psychomotor Performance; Triazolam | 1999 |
Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Cues; Discrimination Learning; Discrimination, Psychological; Female; Humans; Hypnotics and Sedatives; Male; Mental Recall; Pentobarbital; Psychomotor Performance; Pyridines; Surveys and Questionnaires; Triazolam; Zolpidem | 2000 |
12 other study(ies) available for triazolam and caffeine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports.
Topics: Adult; Caffeine; Discrimination Learning; Female; Humans; Male; Microcomputers; Psychomotor Performance; Reaction Time; Triazolam | 1992 |
Subjective and objective measures of sleepiness: effect of benzodiazepine and caffeine on their relationship.
Topics: Adult; Anti-Anxiety Agents; Caffeine; Double-Blind Method; Electrocardiography; Electroencephalography; Electrooculography; Flurazepam; Humans; Male; Sleep; Sleep, REM; Triazolam | 1991 |
Effects of alprazolam, caffeine, and zolpidem in humans trained to discriminate triazolam from placebo.
Topics: Adolescent; Adult; Alprazolam; Analysis of Variance; Caffeine; Discrimination, Psychological; Female; GABA Agonists; GABA Modulators; Humans; Male; Phosphodiesterase Inhibitors; Pyridines; Triazolam; Zolpidem | 2001 |
[Strategies against jet lag].
Topics: Anti-Anxiety Agents; Caffeine; Central Nervous System Stimulants; Complementary Therapies; Homeopathy; Humans; Jet Lag Syndrome; Melatonin; Time Factors; Triazolam | 2004 |